Recent Updates
Recently added Catalysts
KRMD Positive Sentiment Score: 70/100

KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Key Takeaway: KORU Medical Systems, Inc. will report its fourth quarter and full year 2025 financial results on March 12, 2026. A conference call and webcast will follow at 4:30 p.m. ET for management to discuss the results and provide a corporate update. The company specializes in large volume subcutaneous infusion solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • KORU Medical is focused on innovative patient-centric solutions.
  • The upcoming financial results may indicate positive growth.
  • Management will provide a corporate update, enhancing transparency.

Full Press Release Details

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on theNews/Eventspage of the Investors section of KORU Medical’s website atwww.korumedical.com. The archived webcast will be available for six months.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60®and FreedomEdge®Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visitwww.korumedical.com.
Investor Contact:Louisa Smithinvestor@korumedical.com

Frequently Asked Questions

When will KORU Medical report its financial results?

KORU Medical will report its fourth quarter and full year 2025 financial results on March 12, 2026.

What time is the conference call for KORU Medical's results?

The conference call will take place at 4:30 p.m. ET on March 12, 2026.

How can I access the conference call?

The call can be accessed by dialing (877)-407-0784 for U.S. participants or (201)-689-8560 for international callers.

What products does KORU Medical specialize in?

KORU Medical specializes in large volume subcutaneous infusion solutions.

Last updated: Feb 27, 2026